We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Developed for Legionnaires' Disease

By LabMedica International staff writers
Posted on 29 Sep 2011
Separate measurement of antibodies to Legionella pneumophila serogroups as single antigens can facilitate an early diagnosis of Legionnaires' disease.

An enzyme-linked immunosorbent assay (ELISA) was developed and evaluated to determine whether separate measurement of immunoglobulin (Ig) M and G antibodies to L. pneumophila serogroups 1, 3 and 6 as single antigens can assist in the diagnosis.

Scientists at the Statens Serum Institut (Copenhagen, Denmark) compared the ELISA with an in-house indirect Legionella immunofluorescence antibody test (IFAT) measuring Total Ig. A total of 193 sera from 128 patients with confirmed L. pneumophila infections were used to assess the sensitivity of the developed ELISA. The sensitivity was assessed in different time-periods after onset of symptoms. L. pneumoniae infection was confirmed by one or more of the following methods: culture by standard method, Legionella urinary antigen EIA (Biotest AG, Dreieich, Germany), and an in-house polymerase chain reaction (PCR) method.

It was found that the sensitivity of the ELISA increased during the first month of infection, IgM being the most sensitive; ranging from 13% in the first week after onset of symptoms, 45% in the second week to 84% in the third week; in the fourth week and beyond, a drop to 67% was discerned. The IFAT detecting L. pneumophila subgroups 1–6 had a sensitivity of 11%, 27%, 80%, and 59%, respectively, during these time-periods. The test with the lowest sensitivity during these time-periods was the IgG ELISA (0%, 21%, 36%, and 52%) respectively, but by combining the IgG results with the IgM results, the overall sensitivity of the assay was improved (13%, 48%, 88%, and 70%), respectively.

The in-house methods IgM ELISA and IFAT both had a low false positive rate: 7% and 4% among 75 samples. In contrast, the IgG ELISA had a false positive rate of 14%, which was high compared to the other tests. The sera which were positive for Helicobacter pylori, Salmonella typhimurium/enteritidis, and Mycoplasma pneumoniae showed the highest rate of false positive in the IgG subgroup1 ELISA. The sera, which caused the false positive results in the IFAT and IgM ELISA were the sera with antibodies to Proteus species and S. typhimurium/enteritidis.

The study confirmed that detection of IgG and IgM antibodies by ELISA is an important diagnostic tool especially during the initial phase of the disease, when supported by other tests like the urinary antigen test, PCR, or culture of the organism. The authors concluded that specific antibodies against L. pneumophila subgroups 1, 3, and 6 can be detected in patients early in the course of infection. Furthermore, positive IgM level can be used as a good indicator of an ongoing or recent Legionella infection. The study was published in September 2011, in the Journal of Microbiological Methods.

Related Links:
Statens Serum Institut
Biotest AG



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.